Revenue +12.5% YoY, but PAT -28.2%: Margin pressure masks bullish capacity story
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Guidance cut from ₹800 Cr to ₹750 Cr (6.25% lower); prior margin targets (28-29%) not in sight yet (Q2 20.8%)
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong multi-year expansion thesis (Phase-3 + order book ₹550+ Cr) is offset by Q2 profitability decline (PAT −28.2% YoY) and guidance cut (₹800 Cr → ₹750 Cr). Margin compression from freight/raw-material costs is real near-term; recovery hinges on export mix tilt + cost pass-through.
₹192.6 Cr
Revenue · +12.5% YoY₹33 Cr
Reported PAT · −28.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
FY27 revenue guidance of ₹800 Cr remains on track
MISSMD now says ₹750 Cr target; ₹800 Cr prior guidance is withdrawn
EBITDA margin improving from Q1 to Q2
METQ2 20.8% EBITDA margin vs Q1 16.4%; confirmed in numbers
Exports 40% domestic, 60% export in Q2
OVERSTATEDMD says 'anywhere between probably 40% to 60%' — evasive on exact mix
RAW material costs stabilizing; margin recovery likely
OVERSTATEDQ2 EBITDA margin 20.8% vs 28-29% historical; freight/logistics still elevated
Order book ₹550+ Cr covers 6+ months
METH1 revenue ₹330 Cr; H2 needs ₹500+ Cr for ₹750 Cr full-year target — executable but tight
Earnings quality
What changed since the last call
FY27 revenue guidance cut
DowngradePrior: ₹800 Cr. Now: ₹750 Cr (implicit, ~₹50 Cr or 6.25% lower). Not formally restated.
Margin trajectory delayed
DowngradeQ2 EBITDA margin 20.8% vs 28-29% prior. Freight/RM cost headwinds persist; recovery now Q3 target, not Q2.
Export recovery momentum
UpgradeU.S. tariff withdrawn Feb 2026; North America orders accelerating. Middle East crisis impact fading. Export outlook now >40%.
Phase-3 expansion on track
NeutralApril 2027 commissioning confirmed; 6,500 MVA, 220 kV entry expected 3–6 months post-live. Unchanged vs prior.
The Q&A
Analysts pressed hard on margins (freight impact in %), working capital sustainability, capacity competition, and exact export-domestic margin delta. Alay Shah was confident but evasive on percentages; Q&A tone was tense on the PAT decline vs revenue growth mismatch.
Working capital sustainability — Aadesh Gosalia, Spark Capital
AnsweredWC is normal for growth. Receivables are interest-bearing (180-day LC to customer, established after initial 60-day LC). Financial assets reflect new project investment. Not alarming given LC interest earned.
Revenue recognition timing — Aadesh Gosalia, Spark Capital
PartialPart deferred from Q1 (₹30–35 Cr), part new orders from improved market. Going forward, more than INR750 Cr quarterly run rate expected.
EBITDA margin outlook — Jiten Parmar, Aurum Edge
PartialFreight is transient; once demand grows and new capacity adds, margin to maintain high EBITDA. Cannot guarantee 30% percentage, but absolute EBITDA ₹200–225 Cr on ₹750 Cr revenue is target.
Capacity utilization & competition — Prathamesh Sawant, Abakkus Investment
AnsweredWe are exporting; others are domestic-focused. Export EBITDA much higher. Higher MVA (lower volume, higher margin) vs peers' commodity models. Margin resilience from export mix and efficiency.
U.S. market dynamics — Ravi Swaminathan, Avendus Spark
AnsweredTariff withdrawn Feb 2026; orders steadily increasing. Lead-time for higher kV is 1–1.5 years. Demand pent-up post-tariff. Supply to U.S. now 40–60% export mix likely.
Export-domestic margin spread — Het Shah, Quantum AMC
DodgedExport EBITDA margins much higher than domestic. Cannot disclose exact figures; mix of customers/products. Focus on balance in order execution.
220 kV entry strategy — Maitri, Sapphire Capital
AnsweredApprovals 3–6 months post-plant live (April 2027). Margins will remain same as current. No premium. Existing customers already verbal committed to take 220 kV once approved.
Profitability under expansion — Rahul Majethia, Eiko Quantum
PartialGrowth requires margin compression short-term. But brand + customer confidence will restore it. Demand is high; we won't be stagnant. Expansion pays off in 2-3 years.
220 kV manufacturing timeline — Mohammed Nameer, Eiko Quantum
AnsweredLower kV 3-6 months lead-time; higher kV >1 year. FY29 100% utilization planned. Phase-3 adds 6,500 MVA; total 14,000 MVA breakeven 35-40% utilization.
Raw material margin resilience — Basant Bansal, NBG Investments
PartialNot sure costs will fall. But pricing is passing through to customers now. New orders at current RM prices, so margins will improve.
FY28-29 revenue and M&A — Nirav, Individual Investor
AnsweredNot conservative. FY28 ₹1,000 Cr, FY29 ₹1,250–1,500 Cr. At 100% capacity, max ₹1,500 Cr. Exploring M&A in related segments.
Guidance
FY27 ₹750 Cr (revised down from ₹800 Cr)
MediumH1 ₹330 Cr delivered; H2 needs ₹420 Cr to hit ₹750 Cr. Order book ₹550+ Cr but execution risk remains.
FY28 ₹1,000 Cr; FY29 ₹1,250–1,500 Cr
MediumContingent on Phase-3 ramp, export recovery, 220 kV approvals. At 100% capacity, max ₹1,500 Cr.
FY27 EBITDA ₹200–225 Cr (~26.7%–30% on ₹750 Cr)
LowQ2 20.8% margin; historically 28-29%. Freight/RM cost headwinds persist; recovery depends on export tilt + cost pass-through.
FY28+ margins to improve further with higher export %, Phase-3 ramp
MediumQualitative; no specific % given. Contingent on cost stabilization and demand durability.
Phase-3 (6,500 MVA) commissioned April 2027; total capacity 14,000 MVA
HighCivil, PEB, utility work on track. Production equipment ordered. No delay flagged.
Risks the call surfaced
Margin compression
HighQ2 EBITDA 20.8% vs 28-29% historical. Freight/raw-material costs elevated. If export mix stalls, margin floor stays 20-22%.
Guidance credibility
HighFY27 guidance downgraded from ₹800 Cr to ₹750 Cr without formal restatement. Margin targets (₹200–225 Cr EBITDA) not yet on trajectory. Analysts may question guidance rigor.
Execution risk (Phase-3)
MediumPhase-3 (6,500 MVA, 220 kV) commissioning April 2027 is tight timeline. Approval for 220 kV transformer class 3-6 months post-live. If delayed, revenue ramp to ₹1,000 Cr (FY28) at risk.
Capacity oversupply risk
MediumIndustry-wide capacity expansion (Wauree, others) may pressurize pricing. Shilchar's edge is export + higher-MVA product, but oversupply could compress margins further.
Working capital cycle elongation
LowWC increased to ₹200 Cr in H1. If sales ramp without cash conversion, cash drag could stress liquidity during Phase-3 capex.
Management
Score 6/10. Transparent on operational metrics but evasive on margin specifics. Alay Shah confident on long-term thesis but vague on near-term execution. Did not formally restate downgraded FY27 guidance (₹800 Cr → ₹750 Cr). Phase-3 on track (April 2027 commissioning). Order book ₹550+ Cr validates demand. But PAT fell 28.2% YoY despite revenue growth — margin compression not fully attributed to transient costs.
1 · Q3 FY27
100% capacity utilization; export EBITDA margin inflection
2 · April 2027
Phase-3 commissioning; 220 kV approvals expected in parallel
3 · H2 FY27
Need ₹500+ Cr revenue to hit revised ₹750 Cr target
Margin compression from freight/raw-material costs is real near-term; recovery hinges on export mix tilt + cost pass-through.
Shilchar Technologies Q2 FY27: PAT slides 28% YoY as margins compress on costlier inputs
PAT -28.21% YoY · revenue +12.45% · margins compressing
₹192.61 Cr
+12.45% YoY
₹32.98 Cr
-28.21% YoY
16.54%
-8.9pp YoY
₹28.83
Shilchar Technologies' standalone Q2 FY27 (quarter ended 30 September 2026) revenue of ₹192.61 Cr grew 12.5% YoY (₹171.28 Cr in Q2 FY26), but net profit fell 28.2% YoY to ₹32.98 Cr from ₹45.94 Cr, as operating margin compressed to 20.80% from 31.29% and net margin to 16.54% from 25.47%. Sequentially the quarter looks far stronger — PAT up 58.1% and revenue up 43.1% over Q1 FY27 (₹20.86 Cr PAT, ₹134.61 Cr revenue) — but per our YoY-primary read that QoQ jump mostly reflects a soft Q1 base rather than a turnaround, since this is an order-driven transformer business, not a seasonal one. EPS came in at ₹28.83 versus ₹40.15 a year ago and ₹18.24 last quarter. No exceptional items appear in the statement, so the YoY profit decline is entirely operational.
Q2 FY-2027 vs prior quarters
The margin squeeze traces to raw materials: cost of materials consumed rose to 70.4% of revenue this quarter from 59.8% in Q2 FY26, while employee costs and other expenses held roughly flat as a share of revenue. This lines up with management's own August 2026 concall framing — FY27 EBITDA margin restoration to the ~29% historical band was pegged to export recovery from the West Asia crisis, with a 'slight dip' flagged if the business stayed domestic-focused; the actual OPM compression to 20.80% is materially sharper than 'slight', suggesting exports have not yet normalized. H1 FY27 revenue of ₹327.22 Cr also runs behind the ₹800 Cr full-year guidance pace, needing roughly ₹473 Cr in H2 — a ~44% step-up over H1 — to hit the target. We found no analyst consensus estimates specific to this quarter, so the print's standing versus Street is unknown; management issued no separate press release beyond the regulatory filing, and the Phase-3 capacity expansion (6,500 MVA, flagged for April 2027 commissioning) is not addressed here. Next quarter should show whether the sequential margin recovery (16.38% OPM in Q1 to 20.80% now) continues toward the 29% target or whether input-cost pressure persists.
The stock went into the print at ₹3,797.6, down 7.5% over the past month of trading.
For context: revenue is at a 6-quarter high.
What the summary numbers don't show
Board approved unaudited results on 28 Oct 2026 — reviewed by statutory auditors (CNK & Associates) with no qualifications
FY27 revenue ₹800 Cr guidance maintained but conditioned on export recovery from West Asia crisis. EBITDA margin restoration to 29% historicals contingent on exports normalizing; if domestic-focused, 'slight dip' expected. Phase-3 expansion (6,500 MVA) on track for April 2027 commissioning; initially lower 220 KV margi
— This quarter: missed
W1
H2 FY27 revenue trajectory against the ₹800 Cr full-year guidance — needs ~₹473 Cr in H2 vs ₹327 Cr booked in H1
W2
Whether OPM recovers toward management's flagged ~29% historical EBITDA-margin band as exports normalize, or stabilizes near the current ~21%
W3
Raw material cost ratio (70.4% of revenue this quarter, up from 59.8% YoY) — next quarter shows if this is transient or structural
Only standalone statement exists (no consolidated section); converted from ₹ Lakhs; no exceptional items in the statement; OPM/NPM recomputed from the expense breakup and matched the supplied comparison-context figures almost exactly, confirming the methodology.
Revenue Rises, Profit Falls — The Real Story Behind the Expansion
Q2 delivered 12.5% revenue growth but a 28.2% profit decline. The margin compression is real, management quietly cut full-year guidance, and the bull case now depends entirely on Phase-3 execution and export mix tilt.
₹192.6 Cr
+12.5% YoY, +43% QoQ
₹33.0 Cr
−28.2% YoY, +58% QoQ
20.8%
vs 16.4% Q1, vs 28–29% historical
₹750 Cr
revised down from ₹800 Cr
The Gap That Defines the Quarter
On paper, Q2 looks strong: revenue up 12.5%, order book healthy at ₹550+ Cr, Phase-3 expansion on track. But the one number that matters — profit — fell 28.2% year-on-year. That disconnect is not a typo; it is the quarter. Revenue came in, but margin didn't follow. Freight and raw material costs, elevated from Middle East crisis fallout and global supply tightness, ate away at the bottom line. EBITDA margin of 20.8% sits 7–8 percentage points below historical 28–29% levels. Management's answer: transient. The market's answer: a 34% drawdown from the all-time high of ₹5,399.
What Management Claimed vs. What Holds Up
FY27 revenue guidance of ₹800 Cr on track
ContradictedMD now targeting ₹750 Cr. Prior ₹800 Cr guidance withdrawn but never formally restated on call.
EBITDA margin improving Q1 to Q2
SupportedQ1 16.4%, Q2 20.8% — confirmed in the numbers. +440 bps QoQ is real.
Export mix 40% domestic, 60% export
OverstatedMD said 'anywhere between probably 40% to 60%' when pressed. Non-committal band, not a clear split.
Raw material costs stabilizing; margin recovery likely
OverstatedRM at 71–72% of sales (vs 60% prior). MD admits 'not sure costs will fall.' Pricing pass-through to customers 'now starting.'
Order book ₹550+ Cr covers 6+ months
SupportedH1 revenue ~₹330 Cr; H2 needs ~₹420 Cr to hit ₹750 Cr full-year. Order book supports execution but margin is tight.
What Changed on This Call
FY27 revenue guidance cut from ₹800 Cr to ₹750 Cr (~6.25% reduction, not formally restated)
EBITDA margin recovery timeline pushed to Q3+ (not achieved in Q2 as prior optimism suggested)
Export momentum confirmed recovering post-US tariff removal (Feb 2026); North America lead-times 1–1.5 years
Phase-3 (6,500 MVA, 220 kV class) commissioning April 2027 remains on track; total capacity 14k MVA
FY28 target ₹1,000 Cr, FY29 ₹1,250–1,500 Cr reiterated; contingent on Phase-3 ramp and export mix hold
Reconciling the Margin Story
In H1, raw material costs rose from 60% to 71–72% of sales. Freight, still elevated from Middle East supply disruptions, added further drag. Q2 EBITDA of ₹40.06 Cr represents a 20.8% margin — better than Q1's 16.4%, but a structural 7–8 pp gap versus 28–29% historical levels. Management's thesis: three levers close the gap. First, export revenue tilt. Exports command materially higher EBITDA margins than domestic (exact % undisclosed), and post-tariff momentum in North America is real. Second, capacity utilization moving from 80–90% to 100% by Q3, driving scale economies. Third, raw material cost pass-through on new orders now 'starting.' But none of these are guaranteed. Export demand could stall, new capacity could cannibalize margins industry-wide (Wauree and peers are all expanding), and pricing power may not hold if demand softens.
The RM prices have stabilized. Again, it is not as what it used to be. And I don't think that it will completely stabilize till all the Middle East crisis and other things gets concluded.
The Bull-Bear Ledger
Phase-3 expansion (April 2027) adds 6,500 MVA and unlocks 220 kV approvals in 3–6 months post-live
Order book ₹550+ Cr validates demand; FY28 ₹1,000 Cr target is quantified not speculative
Export recovery post-US tariff withdrawal is concrete (lead-time 1–1.5 years, pent-up demand)
PAT fell 28.2% YoY despite revenue growth — margin compression is structural, not transient
FY27 guidance quietly cut 6.25% (₹800 Cr → ₹750 Cr); margin targets (28–29%) not in sight
Industry-wide capacity glut (Wauree, others expanding) threatens pricing power near-term
Working capital up to ₹200 Cr in H1; cash drag during Phase-3 capex if sales ramp stalls
Management tone confident but vague on margin specifics; evasive when pressed on export % and RM cost headwinds
Risks, Ranked by How Much They Should Concern a Holder
Margin recovery doesn't materialize (stuck at 20–22% vs 28–29% historical)
HighPAT decline despite revenue growth suggests structural headwind, not transient. If freight/RM normalisation takes years or doesn't happen, FY27–28 earnings growth stalls. Street already priced in margin compression; further disappointment triggers repricing.
Guidance credibility. FY27 cut from ₹800 Cr to ₹750 Cr without formal restatement
HighAnalysts had to infer downgrade. If H2 misses ₹420 Cr revenue (needs to hit ₹750 Cr), another cut likely. Damages forward guidance confidence for FY28 ₹1,000 Cr target.
Phase-3 execution delay or 220 kV approval >6 months post-live
MediumApril 2027 commissioning is tight. If delayed, FY28 ramp to ₹1,000 Cr at risk. 220 kV class is key differentiation; delay erodes margin restoration thesis.
Export market volatility (Middle East, Europe geopolitical) or North American demand softening post-tariff recovery
MediumBull case relies on 50–60% export mix and higher export EBITDA margins. If export orders disappoint, company reverts to higher-mix domestic (lower margin) to absorb capacity.
Industry oversupply pressures pricing further
MediumWauree, others adding capacity. If transformer pricing deteriorates below RM cost inflation, margin floor erodes. Management's 'higher-MVA premium' may not hold.
Working capital cycle elongates during Phase-3 capex ramp
LowWC already ₹200 Cr in H1. If sales ramp without cash conversion acceleration, liquidity stress. Mitigated by interest-bearing LC structure, but cash drag remains.
How the Street Is Positioned
The stock sits at ₹3,565.8, down 34% from its all-time high of ₹5,399 and trading below its 20-, 50-, and 200-day moving averages (₹3,810, ₹3,951, and ₹4,083 respectively). RSI at 38.2 signals neutral momentum — not oversold, but heavy. Volume is normal, not panic. The sharp drawdown aligns perfectly with the fundamental story: the market priced in expansion upside; Q2 delivered margin compression and a guidance cut instead. Ownership remains stable — FII at 2.57%, DII at 1.95%, promoter at 62.12% — no distress selling. The bearish price action is not a warning of hidden problems; it is the market rationally repricing the earnings outlook. The bull case (Phase-3 + export recovery → ₹1,000 Cr FY28 + margin restoration) is still intact, but the path is narrower and riskier than prior consensus assumed.
The Debate
What to Watch Next
1 · H2 FY27 revenue delivery
H1 delivered ~₹330 Cr. H2 needs ₹420 Cr to hit revised ₹750 Cr full-year target. Order book ₹550+ Cr supports execution, but this is the first real test of guidance rigor. Miss here, and another downgrade is likely.
2 · Q3 FY27 EBITDA margin
Management targeted 100% capacity utilization and margin inflection by Q3. If Q3 EBITDA margin doesn't reach 23–24%+, cost pass-through is stalling and FY28 margin recovery story breaks.
3 · Phase-3 April 2027 commissioning and 220 kV approval timeline
April live date must hold; any 4-week slip delays 220 kV approvals into Q3-Q4 FY28, deferring revenue ramp. Approvals within 3–6 months post-live are critical for FY28 ₹1,000 Cr credibility.
Shilchar is not broken, but it's not the growth story the market was trading last year. Revenue is real, order book is real, expansion is real. But the margin compression from freight and raw material cost inflation exposed a near-term vulnerability the prior call glossed over. The 34% drawdown from ATH is not irrational; it reflects a repricing of the earnings path, not a repricing of the business fundamentals.
Hold if you own it and believe Phase-3 + exports close the margin gap by FY28-end. The stock could re-rate to ₹4,500–5,000 if execution is clean. But the bar for credibility is high now — every quarter counts. The number to track from here is EBITDA margin, quarter on quarter. If Q3–Q4 FY27 margins stay in the 20–22% range, the long-term thesis is at risk. If they inflect to 24%+, the bull case validates and the stock rallies. The debate will be won or lost in the next two earnings prints.